• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.

作者信息

Visani Giuseppe, Breccia Massimo, Gozzini Antonella, Specchia Giorgina, Montefusco Enrico, Morra Enrica, Annunziata Mario, Camera Andrea, Cavazzini Francesco, Stagno Fabio, Pregno Patrizia, Usala Emilio, Santini Valeria, Piccaluga Pier Paolo, Isidori Alessandro

出版信息

Am J Hematol. 2010 Dec;85(12):960-3. doi: 10.1002/ajh.21871.

DOI:10.1002/ajh.21871
PMID:21069865
Abstract
摘要

相似文献

1
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.达沙替尼即使在低剂量时，对于对伊马替尼耐药或不耐受的慢性髓性白血病患者也是一种有效的二线治疗药物。这是一项基于现实生活的意大利多中心回顾性研究对114例患者得出的结果。
Am J Hematol. 2010 Dec;85(12):960-3. doi: 10.1002/ajh.21871.
2
[Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].达沙替尼治疗慢性期慢性髓性白血病的伊马替尼耐药和不耐受患者
Ter Arkh. 2009;81(7):41-6.
3
Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.达沙替尼治疗伊马替尼耐药或不耐受的 CML 患者：来自捷克共和国 6 家血液学中心临床实践的数据。
Neoplasma. 2010;57(4):355-9.
4
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.达沙替尼用于伊马替尼耐药的费城染色体阳性白血病。
N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.
5
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.达沙替尼：从治疗对伊马替尼耐药或不耐受的慢性髓性白血病患者到治疗新诊断的慢性期慢性髓性白血病患者。
Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.
6
Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.每日一次达沙替尼用于治疗慢性髓性白血病患者。
Ann Pharmacother. 2009 May;43(5):920-7. doi: 10.1345/aph.1L570. Epub 2009 Mar 31.
7
Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.伊马替尼治疗慢性髓性白血病：其有效性和长期副作用的影响
J Natl Cancer Inst. 2011 Apr 6;103(7):527-9. doi: 10.1093/jnci/djr073. Epub 2011 Mar 21.
8
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
9
Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.达沙替尼与高剂量伊马替尼治疗对标准剂量伊马替尼耐药的慢性髓性白血病（CML）患者的成本效益：瑞典模型应用。
Acta Oncol. 2010 Aug;49(6):851-8. doi: 10.3109/0284186X.2010.495132.
10
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.α干扰素预处理的慢性粒细胞白血病患者对伊马替尼（格列卫）反应的分子监测。低水平的残留病与持续缓解相关。
Leukemia. 2003 Sep;17(9):1687-94. doi: 10.1038/sj.leu.2403033.

引用本文的文献

1
Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia.基于治疗药物监测的达沙替尼剂量优化在慢性期慢性髓性白血病患者中的应用
Drug Des Devel Ther. 2025 May 23;19:4311-4320. doi: 10.2147/DDDT.S521260. eCollection 2025.
2
Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia - You can do this at home if you read the instructions.慢性粒细胞白血病患者停用酪氨酸激酶抑制剂——如果您阅读说明书，您可以在家自行操作。
Haematologica. 2019 Aug;104(8):1508-1511. doi: 10.3324/haematol.2019.222216.
3
What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature.
达沙替尼治疗慢性髓性白血病的最佳剂量和给药方案是什么：两例病例报告及文献综述
Oncol Res. 2016 Jan 21;23(1-2):1-5. doi: 10.3727/096504015X14452563485986.
4
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).达沙替尼可使新诊断的慢性期慢性髓性白血病患者快速且深度缓解：一项随机2期研究（NordCML006）的临床结果
Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13.
5
The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
Haematologica. 2011 Apr;96(4):e23-4; author reply e25. doi: 10.3324/haematol.2011.041319.